The European Medicines Agency (EMA) has recommended granting marketing authorisation for Rasonque (daraxonrasib), a new treatment option for adults with metastatic pancreatic cancer who have previously received at least one systemic treatment.
This marks an important development in pancreatic cancer treatment, particularly for patients whose disease has progressed following initial therapy and who have limited treatment options.
Encouraging clinical trial results
Daraxonrasib, developed by Revolution Medicines, is an oral treatment designed to inhibit RAS proteins involved in cancer cell growth.
The EMA’s recommendation follows a multinational Phase 3 study involving 500 patients with metastatic pancreatic adenocarcinoma whose disease had worsened after previous systemic treatment.
Patients treated with daraxonrasib had a median overall survival of 12.4 months, compared with 6.7 months for those receiving chemotherapy. Median progression-free survival was 7.2 months compared with 3.6 months, respectively.
These findings represent encouraging progress in an area where new and effective treatment options are urgently needed.
What happens next?
The EMA’s positive recommendation is an important regulatory milestone, but it does not yet constitute final EU marketing authorisation.
The European Commission will now consider the recommendation and make a final decision. If authorised, decisions about pricing and reimbursement will be made at national level, according to each country’s healthcare system.
PCE’s commitment to the pancreatic cancer community
Pancreatic Cancer Europe (PCE) welcomes this promising development and recognises its potential significance for patients and families affected by metastatic pancreatic cancer.
As further regulatory decisions are made, PCE will continue to follow developments closely and work to share clear, reliable and accessible information with the pancreatic cancer community across Europe.
Ensuring that patients, caregivers and patient organisations are informed about emerging treatment options and developments in access to care remains an important part of PCE’s work.